TScan Therapeutics Inc. (TCRX)
TScan Therapeutics Statistics
Share Statistics
TScan Therapeutics has 52.31M shares outstanding. The number of shares has increased by 7.05% in one year.
| Shares Outstanding | 52.31M |
| Shares Change (YoY) | 7.05% |
| Shares Change (QoQ) | 6.03% |
| Owned by Institutions (%) | 34.99% |
| Shares Floating | 46.81M |
| Failed to Deliver (FTD) Shares | 1.77K |
| FTD / Avg. Volume | 0.39% |
Short Selling Information
The latest short interest is 2.03M, so 3.58% of the outstanding shares have been sold short.
| Short Interest | 2.03M |
| Short % of Shares Out | 3.58% |
| Short % of Float | 4.33% |
| Short Ratio (days to cover) | 3.49 |
Valuation Ratios
The PE ratio is -2.67 and the forward PE ratio is -1.26. TScan Therapeutics's PEG ratio is 0.17.
| PE Ratio | -2.67 |
| Forward PE | -1.26 |
| PS Ratio | 120.9 |
| Forward PS | 0.6 |
| PB Ratio | 1.41 |
| P/FCF Ratio | -2.97 |
| PEG Ratio | 0.17 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for TScan Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 8.14, with a Debt / Equity ratio of 0.27.
| Current Ratio | 8.14 |
| Quick Ratio | 8.14 |
| Debt / Equity | 0.27 |
| Debt / EBITDA | -0.55 |
| Debt / FCF | -0.57 |
| Interest Coverage | -36.91 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $14.52K |
| Profits Per Employee | $-657.21K |
| Employee Count | 194 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -77.78% in the last 52 weeks. The beta is 1.08, so TScan Therapeutics's price volatility has been higher than the market average.
| Beta | 1.08 |
| 52-Week Price Change | -77.78% |
| 50-Day Moving Average | 1.67 |
| 200-Day Moving Average | 4.02 |
| Relative Strength Index (RSI) | 58.71 |
| Average Volume (20 Days) | 451.37K |
Income Statement
In the last 12 months, TScan Therapeutics had revenue of 2.82M and earned -127.5M in profits. Earnings per share was -1.14.
| Revenue | 2.82M |
| Gross Profit | 2.82M |
| Operating Income | -134.82M |
| Net Income | -127.5M |
| EBITDA | -119.74M |
| EBIT | -123.85M |
| Earnings Per Share (EPS) | -1.14 |
Balance Sheet
The company has 178.69M in cash and 65.31M in debt, giving a net cash position of 113.38M.
| Cash & Cash Equivalents | 178.69M |
| Total Debt | 65.31M |
| Net Cash | 113.38M |
| Retained Earnings | -375.1M |
| Total Assets | 371.12M |
| Working Capital | 256.77M |
Cash Flow
In the last 12 months, operating cash flow was -110.82M and capital expenditures -3.83M, giving a free cash flow of -114.65M.
| Operating Cash Flow | -110.82M |
| Capital Expenditures | -3.83M |
| Free Cash Flow | -114.65M |
| FCF Per Share | -1.02 |
Margins
Gross margin is 100%, with operating and profit margins of -4787.68% and -4527.66%.
| Gross Margin | 100% |
| Operating Margin | -4787.68% |
| Pretax Margin | -4527.66% |
| Profit Margin | -4527.66% |
| EBITDA Margin | -4252.06% |
| EBIT Margin | -4787.68% |
| FCF Margin | -4071.27% |
Dividends & Yields
TCRX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for TCRX is $10, which is 509.8% higher than the current price. The consensus rating is "Buy".
| Price Target | $10 |
| Price Target Difference | 509.8% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
Scores
| Altman Z-Score | -1.27 |
| Piotroski F-Score | 3 |